Patents by Inventor Patrick Y. Lu

Patrick Y. Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9506063
    Abstract: The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 29, 2016
    Assignee: Sirnaomics, Inc.
    Inventors: Alan Y. Lu, Patrick Y. Lu, David M. Evans, John J. Xu
  • Publication number: 20160279352
    Abstract: A nebulizer composed of shell with air inlet and lid with spray nozzle. Inside the shell, lays, from bottom to top, a drug cup with piezoelectric transducer and spray chamber with spray outlet. Nebulizer includes vertical air vent lying from bottom air inlet, through middle spray nozzle, to top spray outlet. Moreover, an electric fan lies inside air inlet. Components of piezoelectric ceramic transducer are as follows (mass percentage): lead tetraoxide (Pb3O4, 63.3˜68.3%), zirconium dioxide(ZrO2, 14.2˜15.3%), titanium dioxide (TiO2, 8.1˜9.5%), strontium oxide (SrO, 4.6˜5.2%), iron sesquioxide (Fe2O3, 1.5˜1.8%), stannic oxide (SnO2, 1.0˜1.4%), manganese dioxide (MnO2, 0.3˜1.1%), cerium sesquioxide (Ce2O3, 0.5˜0.8%), columbium pentoxide (Nb2O5, 0.4˜0.8%), zinc oxide (ZnO, 0.3˜0.7%). Nebulizer is small in size, with low power consumption and lower cost, and is able to produce mist with small particle size.
    Type: Application
    Filed: September 25, 2014
    Publication date: September 29, 2016
    Inventors: Cheng WANG, Patrick Y. LU, Chuntian LU, Songlin JIANG, Shenggao TANG, Tao YUAN
  • Publication number: 20160068843
    Abstract: The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle.
    Type: Application
    Filed: July 7, 2013
    Publication date: March 10, 2016
    Applicant: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, David M. Evans, John J. Xu, Alan Y. Lu, Qing Ge
  • Patent number: 9012622
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: April 21, 2015
    Inventors: Patrick Y. Lu, David Evans, Jun John Xu
  • Patent number: 8735567
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 27, 2014
    Inventors: Patrick Y. Lu, Ling Li, Vera Simonenko
  • Publication number: 20130345284
    Abstract: The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 26, 2013
    Inventors: Alan Y. Lu, Patrick Y. Lu, David M. Evans, John J. Xu
  • Patent number: 8541568
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: September 24, 2013
    Inventors: Hai Yan, Patrick Y. Lu, Darell D. Bigner
  • Publication number: 20130225655
    Abstract: The present invention provides compositions and methods for using combinations of TGF?1 and Cox-2 inhibitors and TGF?1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGF?1 and Cox-2 at the same time, resulting in significant less scar formation.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 29, 2013
    Inventors: Patrick Y. Lu, Vera Simonenko, David Evans, John J. Xu
  • Publication number: 20130123330
    Abstract: The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds to an mRNA molecule that encodes VEGFR2. In another embodiment, the composition further comprises an siRNA duplex that binds to an mRNA molecule that encodes TGF?1.
    Type: Application
    Filed: July 15, 2012
    Publication date: May 16, 2013
    Inventors: Patrick Y. Lu, John J. Xu, Alan Y. Lu
  • Publication number: 20130115295
    Abstract: This invention provides a composition matter comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell. In one embodiment, a photosensitizer is incorporated into the silica shell. In another embodiment, the composition further comprises a targeting molecule. In still another embodiment, a small interfering RNA (siRNA) molecule is also attached to the silica shell with the targeting molecule. The invention further provides methods for synthesizing such compositions and for using them in therapeutic and diagnostic applications. These applications use infrared or near infrared activation to excite the UCNPs.
    Type: Application
    Filed: November 22, 2010
    Publication date: May 9, 2013
    Inventors: Qiang Wang, Patrick Y. Lu, Harry Hongjun Yang
  • Publication number: 20120115923
    Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of injured tissue during scar formation to promote scar-free wound healing.
    Type: Application
    Filed: December 29, 2006
    Publication date: May 10, 2012
    Applicant: Intradigm Corporation
    Inventors: Wei-Wu He, Patrick Y. Lu
  • Publication number: 20120071540
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.
    Type: Application
    Filed: December 31, 2009
    Publication date: March 22, 2012
    Inventors: Patrick Y. Lu, David Evans, Jun John Xu
  • Publication number: 20110165227
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas.
    Type: Application
    Filed: May 26, 2009
    Publication date: July 7, 2011
    Inventors: Hai Yan, Patrick Y. Lu, Darell D. Bigner
  • Publication number: 20110124710
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 26, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7893243
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7893244
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20110038849
    Abstract: Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 17, 2011
    Applicant: Intradigm Corporation
    Inventors: Frank Y. Xie, Patrick Y. Lu, Martin C. Woodle, Yijia Liu
  • Publication number: 20100319074
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.
    Type: Application
    Filed: November 6, 2008
    Publication date: December 16, 2010
    Applicant: SIR NAOMICS, INC.
    Inventors: Patrick Y. Lu, Ling Li, Vera Simonenko
  • Patent number: 7786092
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 31, 2010
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7781414
    Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: August 24, 2010
    Assignee: Intradigm Corporation
    Inventors: Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Yijia Liu, Quinn Q. Tang, Jun Xu